Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 329-336

  Chang, Fu Lin ^a,b   Ling, Yuh Fang ^a   Lai, Ming Derg ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

Author keywords

Apoptosis; Bladder cancer; Cisplatin; p53

Indexed keywords

CISPLATIN; DNA; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA DEGRADATION; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; CODON; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE II; DNA, COMPLEMENTARY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENES, MDR; GENES, P53; HUMANS; MUTATION; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034113017     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. McGill G and Fisher DE: Apoptosis in tumorigenesis and cancer therapy. Frontiers Biosci 2: 353-379, 1997.
2. Reed JC, Miyashita T and Takayama S et al: BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23-32, 1996.
3. Kastan MB, Onyekwere O, Sidransky D et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
4. Maltzman W, Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689-1694, 1984.
5. Velculescu VE and El Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868, 1996.
6. Lowe SW, Schmitt EM and Smith SW et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
7. Clarke AR, Purdie CA and Harrison DJ et al: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
8. Canman CE, Gilmer TM and Coutts SB et al: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes & Dev 9: 600-611, 1995.
9. Rudin CM and Thompson CB: Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48: 267-281, 1997.
10. Yonish-Rouch E, Resnitzky D and Lotem J et al: Wild-type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interleukin-6. Nature 352: 345-347, 1997.
11. Shaw W, Bovey R and Tardy S et al: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Nat Acad Sci USA 89: 4495-4499, 1992.
12. Fukunaga-Johnson N, Ryan J-J and Wicha M et al: Bcl-2 protects murine erythroleukemia cells from p53-dependent and -independent radiation induced cell death. Carcinogenesis 16: 1761-1767, 1995.
13. Miyake H, Hara I and Gohji K et al: Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res 18: 3087-3092, 1998.
14. Miyake H, Hanada N and Nakamura H et al: Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 16: 933-943, 1998.
15. Cote RJ, Esrig D, Groshen S et al: p53 and treatment of bladder cancer. Nature 385: 123-125, 1997.
16. Yeh MY, Yu DS, Chen SC et al: Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 37: 177-184, 1998.
17. Chen JY, Funk WD and Wright WE et al: Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8: 2159-2166, 1993.
18. Baker SJ, Markowitz S and Fearon ER et al: Suppression of human colorectal carcinoma cell growth by wild type p53. Science 249: 912-915, 1990.
19. Graham FL and Van der Eb AJ: A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456-467, 1973.
20. Harlow E, Williamson NM and Ralston R et al: Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol Cell Biol 5: 1601-1610, 1985.
21. Cheng YT, Li YL and Wu JD et al: Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. Mol Carcinog 13: 173-181, 1995.
22. Isaacs WB, Carter BS and Ewing CM: Wild type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
23. Ginsberg D, Mechta F, Yaniv M and Oren M: Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88: 9979-9983, 1991.
24. Agoff SN, Hou J, Linzer DI and Wu B: Regulation of the human hsp70 promoter by p53. Science 259: 84-87, 1993.
25. Chin KV, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-462, 1992.
26. Subler MA, Martin DW and Deb S: Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 9: 1351-1359, 1994.